Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Elizabeth Hoit Marchlewicz"'
Autor:
Hairong Huo, Stella Min, Amanda M Kong, Deepa S. Subramaniam, Melissa Pavilack, Rahul Shenolikar, Christina Chebili-Larson, Meghan Moynihan, Elizabeth Hoit Marchlewicz
Publikováno v:
Journal of Medical Economics. 24:328-338
Non-small cell lung cancer (NSCLC) with brain metastases (BM) is difficult to treat and associated with poor survival. This study assessed the impact of BM on healthcare-related utilization and costs (HRUC) among patients receiving epidermal growth f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b87054a4b1f755405b84c4813a47b71d
https://doi.org/10.1080/13696998.2021.1885418
https://doi.org/10.1080/13696998.2021.1885418
Publikováno v:
Open forum infectious diseases. 9(7)
Background Limited data are available in the United States on the 12-month epidemiology, outpatient (OP) antibiotic treatment patterns, outcomes, and costs associated with complicated urinary tract infections (cUTIs) in adult patients. Methods A retr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21295a0545a607527edac45eb1541fbb
https://pubmed.ncbi.nlm.nih.gov/35891695
https://pubmed.ncbi.nlm.nih.gov/35891695
Autor:
Aliki Taylor, Ellen Thiel, Matthew Brouillette, Ross A. Soo, Parisa Karimi, Jhanelle E. Gray, Elizabeth Hoit Marchlewicz, W. Sawyer, Takashi Seto
Publikováno v:
Drugs - real world outcomes. 9(1)
Most patients with epidermal growth factor receptor mutation-positive (EGFRm) non-small-cell lung cancer (NSCLC) acquire resistance to first-line (1L) first- or second-generation (1G/2G) EGFR-TKIs; therefore, it is important to optimize 1L treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2680b36b5556d1696814316628b122b5
https://pubmed.ncbi.nlm.nih.gov/34510401
https://pubmed.ncbi.nlm.nih.gov/34510401
Autor:
Vinson Lee, Angela V Bedenbaugh, Machaon Bonafede, Elizabeth Hoit Marchlewicz, Jeyanesh Tambiah
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Angela V Bedenbaugh,1 Machaon Bonafede,2 Elizabeth H Marchlewicz,3 Vinson Lee,4 Jeyanesh Tambiah1 1Biosplice Therapeutics, Inc., San Diego, CA, USA; 2Veradigm Life Sciences, Chicago, IL, USA; 3IBM Watson Health, Cambridge, MA, USA; 4The Kinetix Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2808b9f70c9b55461dabfbeb53dae27c
https://www.dovepress.com/real-world-health-care-resource-utilization-and-costs-among-us-patient-peer-reviewed-fulltext-article-CEOR
https://www.dovepress.com/real-world-health-care-resource-utilization-and-costs-among-us-patient-peer-reviewed-fulltext-article-CEOR
Autor:
George Shrady, Elizabeth Hoit Marchlewicz, Diane J Martinez, Yang Zhao, Steven R. Feldman, Jingchuan Zhang, Lorena Lopez-Gonzalez, Alan M. Mendelsohn
Publikováno v:
Dermatology online journal. 27(1)
Plaque psoriasis is a chronic disease requiring long-term therapy. However, long-term real-world treatment patterns and costs are not well characterized. This study examined treatment patterns and healthcare costs among patients newly initiating a bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::096cd0192d99b053413e4208ac5cbf61
https://pubmed.ncbi.nlm.nih.gov/33560784
https://pubmed.ncbi.nlm.nih.gov/33560784
Autor:
Yang Zhao, Jingchuan Zhang, Alan M. Mendelsohn, George Shrady, Lorena Lopez-Gonzalez, Steven R. Feldman, Diane J Martinez, Elizabeth Hoit Marchlewicz
Publikováno v:
The Journal of dermatological treatment. 32(2)
To compare treatment patterns and costs among psoriasis patients with and without metabolic conditions newly initiating a biologic or apremilast.Adult patients included had ≥1 prescription for secukinumab, adalimumab, ustekinumab, etanercept, or ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfc790439c9b4663587e1bb42487f5b2
https://pubmed.ncbi.nlm.nih.gov/31769703
https://pubmed.ncbi.nlm.nih.gov/31769703
Autor:
Joanne Wu, Angela V Bedenbaugh, Elizabeth Hoit Marchlewicz, Jeyanesh Tambiah, Machaon Bonafede, Vinson Lee
Publikováno v:
Saturday, 15 June 2019.
Background: Knee osteoarthritis (OA) is a painful, disabling condition with increasing prevalence. Objectives: To compare characteristics and treatment patterns of patients newly diagnosed with knee OA by rheumatologists (RH) to those diagnosed by ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4e10ae5263be101f1c2134fadcc39a5
https://doi.org/10.1136/annrheumdis-2019-eular.5212
https://doi.org/10.1136/annrheumdis-2019-eular.5212
Autor:
Jingchuan Zhang, Jashin J. Wu, Elizabeth Hoit Marchlewicz, Alan M. Mendelsohn, George Shrady, Yang Zhao, Diane J Martinez, Steven R. Feldman, Lorena Lopez-Gonzalez
Publikováno v:
Journal of the American Academy of Dermatology. 83:AB80
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ce0da6374685d147001e60c06e8d1f4
https://doi.org/10.1016/j.jaad.2020.06.408
https://doi.org/10.1016/j.jaad.2020.06.408
Autor:
Takashi Seto, Antoinette J. Taylor, Ross A. Soo, Matthew Brouillette, Parisa Karimi, W. Sawyer, Jhanelle E. Gray, Elizabeth Hoit Marchlewicz, Ellen Thiel
Publikováno v:
Annals of Oncology. 30:ix199-ix200
Background Most pts with EGFR mutation-positive (EGFRm) NSCLC develop first-line (1L) EGFR-TKI resistance. Previous analyses of US insurance databases have studied healthcare utilisation and expenditure in pts with EGFRm NSCLC starting first-/second-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d867634f5318835158c062c1394d5eb5
https://doi.org/10.1093/annonc/mdz446.017
https://doi.org/10.1093/annonc/mdz446.017